Barclays analyst Luke Sergott lowered the firm’s price target on West Pharmaceutical (WST) to $265 from $325 and keeps an Equal Weight rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WST:
- West Pharmaceutical Services Signals HVP‑Led Growth Ahead
- Buy Rating on West: Strong Non‑GLP‑1 Growth, Margin Expansion, and Regulatory Tailwinds Support 2026 Outlook
- West Pharmaceutical: Strong Quarterly Beat and Confident 2026 Outlook Support Buy Rating Despite GLP‑1 Concerns
- West Pharmaceutical Services Posts Solid Q4 and 2025 Results
- West Pharmaceutical sees Q1 adjusted EPS $1.65-$1.70, consensus $1.65